From the Cochrane Library: Interventions for Cellulitis and Erysipelas

Ani Oganesyan¹*, BA; Torunn Sivesind¹, MD; Robert Dellavalle¹²*, MPH, MD, PhD
¹University of Colorado School of Medicine, Aurora, CO, United States
²Dermatology Service, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO, United States
*these authors contributed equally

Corresponding Author:
Ani Oganesyan, BA
University of Colorado School of Medicine
13001 E 17th Pl
Aurora, CO, 80045
United States
Phone: 1 8184416860
Email: ani.oganesyan@cuanschutz.edu

(JMIR Dermatol 2022;5(3):e37888) doi: 10.2196/37888

KEYWORDS
eyrispelas; cellulitis; cephalosporins; penicillin; macrolides; intervention; dermatology; skin and soft tissue infections; infection; skin; antibiotics; soft tissue; treatment; therapy; bacterial infection

Cellulitis and erysipelas are types of skin and soft tissue infections (SSTIs) that occur when bacteria, commonly group A beta-hemolytic Streptococcus and Staphylococcus, enter through breaks in the skin. Cellulitis infects the dermis and subcutaneous fat, while erysipelas is a more superficial variant, affecting the superficial dermal lymphatics and adjacent tissues. Untreated, these conditions may result in life-threatening conditions including sepsis, gangrene, or necrotizing fasciitis [1]. Due to the potential risks associated with these conditions, evidence-based research to inform up-to-date treatment guidelines is critical; Table 1 provides guidelines for reference.

A 2010 Cochrane Review [1], “Interventions for Cellulitis and Erysipelas,” assessed 25 randomized controlled trials comparing treatments for primary skin infections, involving a total of 2488 participants. Specifically, the included trials each compared two or more interventions (eg, antibiotics, such as penicillin, macrolides/streptogramins, or cephalosporins, and steroids), routes of administration, and therapy durations. The objective of the review was to assess the efficacy of interventions for nonsurgically acquired SSTIs. This letter will address the limitations of the original review and provide updates based on recent studies.

Macrolides and streptogramins proved superior to penicillin antibiotics in eliminating or reducing cellulitis symptoms (N=2488). Trials comparing oral macrolides against intravenous penicillin found the former to be superior (n=419). No significant differences were found in studies comparing penicillin to cephalosporins (n=88) or among cephalosporin generations (n=538). These comparisons are summarized in Table 2.

Notably, the review [1] highlights a lack of evidence regarding the incorporation of corticosteroids into the antibiotic therapy regimen, whereas subsequent studies have suggested a benefit. The Infectious Disease Society of America states that systemic corticosteroids should be considered in nondiabetic adults to hasten the clinical improvement of cellulitis [2]. A 2018 study [3] assessing corticosteroids (0.5 mg/kg prednisone for 2-3 days) as an add-on therapy to antibiotics for patients hospitalized with erysipelas found that adding steroids resulted in quicker recovery rates and return to full function, with less risk of recurrence [4]. A study of 43 children admitted to the hospital for orbital cellulitis reported a 3-day decrease in length of stay for those treated with adjunctive intravenous dexamethasone (0.3 mg/kg/d every 6 hours for 3 days) compared to those treated with antibiotic monotherapy [3].

Notably, the review [1] did not examine the effectiveness of prophylaxis for cellulitis recurrence; the annual recurrence rate is approximately 8% to 20%. In patients with frequent cellulitis recurrence (3-4 episodes annually), erythromycin, intramuscular penicillin, and oral penicillin VK have been posited as appropriate prophylactic options. A 2021 meta-analysis assessing the use of erythromycin and penicillin found a 69% decreased risk of recurrent cellulitis versus placebo and improved recurrence interval. Penicillin was preferred over erythromycin due to its superior tolerability and cost [5].
Table 1. Current Infectious Diseases Society of America guidelines for the management of nonpurulent cellulitis and erysipelas.\(^a\)

| Disease entity and antibiotic | Dosage, adults | Dosage, children | Comment |
|------------------------------|---------------|-----------------|---------|
| **MSSA\(^b\)** \& **SSTI\(^c\)** | | | |
| Nafcillin or oxacillin | 1-2 g every 4 h IV\(^d\) | 100-150 mg/kg/d in 4 divided doses | Inactive against MRSA\(^e\) |
| Cefazolin | 1 g every 8 h IV | 50 mg/kg/d in 3 divided doses | For penicillin-allergic patients, except those with immediate hypersensitivity reactions; more convenient than nafcillin with less bone marrow suppression |
| Clindamycin | 600 mg every 8 h IV or 300-450 mg 4 times daily by mouth | 25-40 mg/kg/d in 3 divided doses IV or 25-30 mg/kg/d in 3 divided doses by mouth | Bacteriostatic; potential of cross-resistance and emergence of resistance in erythromycin-resistant strains; inducible resistance in MRSA |
| Dicloxacillin | 500 mg 4 times daily by mouth | 25-50 mg/kg/d in 4 divided doses by mouth | Oral agent of choice for methicillin-susceptible strains in adults; rarely used in pediatrics |
| Cephalexin | 500 mg 4 times daily by mouth | 25-50 mg/kg/d 4 divided doses by mouth | For penicillin-allergic patients except those with immediate hypersensitivity reactions; the availability of a suspension and requirement for less frequent dosing |
| Doxycycline, minocycline | 100 mg twice daily by mouth | Not recommended for age <8 y | Bacteriostatic; limited recent clinical experience |
| Trimethoprim-sulfamethoxazole | 1-2 double-strength tablets twice daily by mouth | 8-12 mg/kg (based on trimethoprim component) in either 4 divided doses IV or 2 divided doses by mouth | Bactericidal; efficacy poorly documented |
| **MRSA SSTI** | | | |
| Vancomycin | 30 mg/kg/d in 2 divided doses IV | 40 mg/kg/d in 4 divided doses IV | For penicillin-allergic patients; parenteral drug of choice for treatment of infections caused by MRSA |
| Linezolid | 600 mg every 12 h IV or 600 mg twice daily by mouth | 10 mg/kg every 12 h IV or by mouth for children <12 y | Bacteriostatic; limited clinical experience; no cross-resistance with other antibiotic classes; costly |
| Clindamycin | 600 mg every 8 h IV or 300-450 mg 4 times daily by mouth | 25-40 mg/kg/d in 3 divided doses IV or 30-40 mg/kg/d in 3 divided doses by mouth | Bacteriostatic; potential of cross-resistance and emergence of resistance in erythromycin-resistant strains; inducible resistance in MRSA; important option for pediatrics |
| Daptomycin | 4 mg/kg every 24 h IV | N/A \(^f\) | Bactericidal; possible myopathy |
| Ceftaroline | 600 mg twice daily IV | N/A | Bactericidal |
| Doxycycline, minocycline | 100 mg twice daily by mouth | Not recommended for age <8 y | Bacteriostatic; limited recent clinical experience |
| Trimethoprim-sulfamethoxazole | 1-2 double-strength tablets twice daily by mouth | 8-12 mg/kg/d (based on trimethoprim component) in either 4 divided doses IV or 2 divided doses by mouth | Bactericidal; limited published efficacy data |
| Streptococcal skin infections | Penicillin: 2-4 million units every 4-6 h IV; Clindamycin: 600-900 mg every 8 h IV; Nafcillin: 1-2 g every 4-6 h IV; Cefazolin: 1 g every 8 h IV; Penicillin: VK 250-500 mg every 6 h by mouth; Cephalexin 500 mg every 6 h by mouth | Penicillin: 60,000-100,000 units/kg/dose every 6 h; 10-13 mg/kg dose every 8 h IV; 30 mg/kg/dose every 6 h; 33 mg/kg/dose every 8 h IV | N/A |

\(^a\)Recommendation according to the Infectious Diseases Society of America. Doses listed are not appropriate for neonates. Infection due to *Staphylococcus* and *Streptococcus* species. Duration of therapy is 7 days depending on the clinical response.

\(^b\)MSSA: methicillin-susceptible *Staphylococcus aureus*.

\(^c\)SSTI: skin and soft tissue infection.
Table 2. Treatment comparison with respective results, risk ratio, and CI.

| Comparison                          | Measurement                                                                 | Results                                      | RR^b (95% CI) | Studies, n | Patients, n |
|-------------------------------------|------------------------------------------------------------------------------|---------------------------------------------|---------------|------------|-------------|
| Macrolides/streptogramins vs IV^c penicillin antibiotics | Symptoms rated by participant or medical practitioner                      | Macrolides/streptogramins were superior     | 0.84 (0.73-0.97) | 25         | 2488        |
| Oral macrolide vs IV^c penicillin   | Symptoms rated by participant or medical practitioner                      | Oral therapy was superior                   | 0.85 (0.73-0.98) | 3          | 419         |
| Penicillin vs cephalosporin         | Symptoms rated by participant or medical practitioner                      | No difference in treatment effect           | 0.99 (0.68-1.43) | 3          | 88          |
| Cephalosporin vs cephalosporin^d    | Symptoms rated by participant or medical practitioner                      | No difference in treatment effect           | 1.00 (0.94-1.06) | 6          | 538         |

^aPrimary outcomes included symptoms rated by participant or medical practitioner (eg, duration and intensity of fever, pain, redness of the affected area, swelling of the skin surface and subcutaneous tissue, blister formation), proportion symptom-free (cure), and at a time specified by the study authors, the proportion with severe complications (eg, severe sepsis, multi-organ failure, or death), and quality of life scores (ie, generic and disease-specific items and return to normal activity).

^bRR: relative risk.

^cIV: intravenous.

^dAggregate data from studies evaluating the following cephalosporins: ceftriaxone, cefdinir, cefonicid, cefditoren, cefadroxil, and cefuroxime.

The review reported insufficient data to determine the ideal duration of therapy. International recommendations for treatment duration in SSTIs are inconsistent (5-14 days) [2]—however, this is largely based on expert opinion, with few randomized controlled trials evaluating this parameter. Future research should address this limitation to maximize patient benefit while reducing the effects of prolonged exposure.

Conflicts of Interest

RD is a Joint Coordinating Editor for Cochrane Skin, a dermatology section editor for UpToDate, a Social Media Editor for the Journal of the American Academy of Dermatology (JAAD), a Podcast Editor for the Journal of Investigative Dermatology (JID), Editor-in-Chief of JMIR Dermatology, and a coordinating editor representative on Cochrane Council. TS is an editorial board member-at-large for JMIR Dermatology.

Editorial Notice

The views expressed in this paper are those of the author(s) and in no way represent the Cochrane Library or Wiley. This article is based on a Cochrane Review previously published in the Cochrane Database of Systematic Reviews 2010, Issue 6, DOI: 10.1002/14651858.CD004299 (see www.cochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and Cochrane Database of Systematic Reviews should be consulted for the most recent version of the review.

References

1. Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev 2010 Jun 16(6):CD004299. [doi: 10.1002/14651858.CD004299.pub2] [Medline: 20556757]
2. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014 Jul 15;59(2):147-159. [doi: 10.1093/cid/ciu296] [Medline: 24947530]
3. Chen L, Silverman N, Wu A, Shinder R. Intravenous steroids with antibiotics on admission for children with orbital cellulitis. Ophthalmic Plast Reconstr Surg 2018;34(3):205-208. [doi: 10.1097/IOP.0000000000000910] [Medline: 28369021]
4. Solomon M, Barzilai A, Elphasy H, Trau H, Baum S. Corticosteroid therapy in combination with antibiotics for erysipelas. Isr Med Assoc J 2018 Mar;20(3):137-140 [FREE Full text] [Medline: 29527848]
5. Bystritsky RJ. Cellulitis. Infect Dis Clin North Am 2021 Mar;35(1):49-60. [doi: 10.1016/j.idc.2020.10.002] [Medline: 33494874]

Abbreviations

SSTI: skin and soft tissue infection
